Related Experiment Video
Updated: Nov 15, 2025

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
Published on: June 8, 2022
A case of ramucirumab-induced renal failure with nephrotic-range proteinuria and its pathological findings
Yuta Nakano1, Jiro Kumagai2, Kiyotaka Nagahama3
1Nephrology, Yokohama City Minato Red Cross Hospital, Yokohama, Japan ynakano.kid@tmd.ac.jp.
Abstract:
Ramucirumab-induced renal dysfunction is rarely reported. The pathology of ramucirumab-associated nephropathy in past reports primarily shows thrombotic microangiopathy (TMA) lesions but podocytopathy is not yet known. We report a case of kidney injury induced by ramucirumab in a 71-year-old man with cecal cancer. He was referred to our department for increasing serum creatinine (Cr) levels from 1.08 mg/dL to 2.56 mg/dL after changing anticancer drugs from bevacizumab to ramucirumab. He showed nephrotic-range proteinuria (12.1 g/gCr). A renal biopsy revealed endothelial cell injuries, such as TMA and podocytopathy with epithelial cell hyperplasia, which looked like a crescent. After discontinuing ramucirumab, his renal function and proteinuria improved, as seen by his Cr levels and proteinuria which decreased to 1.74 mg/dL and 1.21 g/gCr, respectively, in 3 months. Unlike previous reports, we found that ramucirumab caused podocyte injuries.
Insights
Ramucirumab can cause kidney injury, including rare podocytopathy, not just thrombotic microangiopathy. Discontinuing the drug improved renal function and proteinuria in a patient with cecal cancer.
Area of Science:
- Nephrology
- Oncology
- Pharmacology
Background:
- Ramucirumab is an angiogenesis inhibitor used in cancer therapy.
- Renal dysfunction is a rare adverse effect of ramucirumab.
- Previous reports linked ramucirumab-induced nephropathy mainly to thrombotic microangiopathy (TMA).
Observation:
- A 71-year-old man with cecal cancer developed worsening kidney injury after switching from bevacizumab to ramucirumab.
- The patient presented with elevated creatinine and nephrotic-range proteinuria.
- Renal biopsy revealed TMA and podocytopathy with crescent formation.
Findings:
- This case demonstrates ramucirumab-induced podocytopathy, a finding not previously described.
- The patient's renal function and proteinuria significantly improved after ramucirumab discontinuation.
Implications:
- Ramucirumab may cause a broader spectrum of kidney injury than previously recognized, including podocyte damage.
- Clinicians should consider ramucirumab-induced nephropathy in patients developing renal dysfunction during treatment.
- Early recognition and drug withdrawal may lead to recovery of kidney function.
More Related Videos
07:38Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin
Published on: May 6, 2018
07:15Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
Related Concept Videos
Nephrotic Syndrome II : Assessment and Medical Management
Renal Corpuscle
Glomerulus: Structure and Function
The glomerulus is a tiny, intricate network of capillaries located at the beginning of the nephron. It's enveloped by the Bowman's capsule and receives its blood supply from an afferent arteriole, which divides into numerous...
Nephrotic Syndrome I : Introduction
Nephrotic Syndrome III : Nursing Management
Factors Affecting Renal Clearance: Renal Impairment
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
Chronic Kidney Disease III: Interprofessional Care